Back to Search
Start Over
Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology
- Source :
- Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 2, Pp 578-593 (2020), Journal of Cachexia, Sarcopenia and Muscle, 11(2), 578-593. WILEY, Journal of Cachexia, Sarcopenia and Muscle
- Publication Year :
- 2019
- Publisher :
- WILEY, 2019.
-
Abstract
- Background:Duchenne muscular dystrophy (DMD) is a fatal muscle‐wasting disorder caused by genetic loss of dystrophin protein. Extracellular microRNAs (ex‐miRNAs) are putative, minimally invasive biomarkers of DMD. Specific ex‐miRNAs (e.g. miR‐1, miR‐133a, miR‐206, and miR‐483) are highly up‐regulated in the serum of DMD patients and dystrophic animal models and are restored to wild‐type levels following exon skipping‐mediated dystrophin rescue inmdxmice. As such, ex‐miRNAs are promising pharmacodynamic biomarkers of exon skipping efficacy. Here, we aimed to determine the degree to which ex‐miRNA levels reflect the underlying level of dystrophin protein expression in dystrophic muscle. Methods:Candidate ex‐miRNA biomarker levels were investigated inmdxmice in which dystrophin was restored with peptide‐PMO (PPMO) exon skipping conjugates and inmdx‐XistΔhsmice that express variable amounts of dystrophin from birth as a consequence of skewed X‐chromosome inactivation. miRNA profiling was performed inmdx‐XistΔhsmice using the FirePlex methodology and key results validated by small RNA TaqMan RT‐qPCR. The muscles from each animal model were further characterized by dystrophin western blot and immunofluorescence staining. Results:The restoration of ex‐myomiR abundance observed following PPMO treatment was not recapitulated in the high dystrophin‐expressingmdx‐XistΔhsgroup, despite these animals expressing similar amounts of total dystrophin protein (~37% of wild‐type levels). Instead, ex‐miRNAs were present at high levels inmdx‐XistΔhsmice regardless of dystrophin expression. PPMO‐treated muscles exhibited a uniform pattern of dystrophin localization and were devoid of regenerating fibres, whereasmdx‐XistΔhsmuscles showed non‐homogeneous dystrophin staining and sporadic regenerating foci. Conclusions:Uniform dystrophin expression is required to prevent ex‐miRNA release, stabilize myofiber turnover, and attenuate pathology in dystrophic muscle.
- Subjects :
- 0301 basic medicine
musculoskeletal diseases
Duchenne muscular dystrophy
Pathology
medicine.medical_specialty
congenital, hereditary, and neonatal diseases and abnormalities
lcsh:Diseases of the musculoskeletal system
lcsh:QM1-695
Dystrophin
Mice
03 medical and health sciences
Exon
Sarcolemma
0302 clinical medicine
Western blot
X‐chromosome inactivation
Physiology (medical)
microRNA
medicine
Extracellular
Animals
Humans
Orthopedics and Sports Medicine
Child
medicine.diagnostic_test
biology
business.industry
X-chromosome inactivation
MicroRNA
Original Articles
lcsh:Human anatomy
medicine.disease
musculoskeletal system
Exon skipping
Disease Models, Animal
MicroRNAs
030104 developmental biology
030220 oncology & carcinogenesis
biology.protein
Biomarker (medicine)
Original Article
Female
lcsh:RC925-935
business
Muscle turnover
Biomarkers
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Journal of Cachexia, Sarcopenia and Muscle, Vol 11, Iss 2, Pp 578-593 (2020), Journal of Cachexia, Sarcopenia and Muscle, 11(2), 578-593. WILEY, Journal of Cachexia, Sarcopenia and Muscle
- Accession number :
- edsair.doi.dedup.....bb13a752d993c0eb60ef9cbcd522405d